Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
- K. Shedden, J. Taylor, +37 authors D. Beer
- Medicine
- Nature Medicine
- 1 August 2008
Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across different… Expand
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
- J. P. Kuebler, H. S. Wieand, +18 authors N. Wolmark
- Medicine
- Journal of clinical oncology : official journal…
- 1 June 2007
PURPOSE
This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy… Expand
Clinical trial designs for predictive marker validation in cancer treatment trials.
- D. Sargent, B. Conley, C. Allegra, L. Collette
- Medicine
- Journal of clinical oncology : official journal…
- 20 March 2005
Current staging and risk-stratification methods in oncology, while helpful, fail to adequately predict malignancy aggressiveness and/or response to specific treatment. Increased knowledge of cancer… Expand
Prognostic factors in colorectal cancer
- C. Compton, L. Fielding, +12 authors C. Willett
- Medicine
- 1 October 2009
Abstract Background.—Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive fa...
- 257
- 15
Vascular Injury Induces Expression of Periostin: Implications for Vascular Cell Differentiation and Migration
- V. Lindner, Q. Wang, B. Conley, R. Friesel, C. Vary
- Biology, Medicine
- Arteriosclerosis, thrombosis, and vascular…
- 28 October 2004
Objective— Periostin mRNA is among the most strongly upregulated transcripts in rat carotid arteries after balloon injury. The goal of the present study was to gain insight into the significance of… Expand
Endoglin Structure and Function
- R. Koleva, B. Conley, +4 authors C. Vary
- Biology, Medicine
- Journal of Biological Chemistry
- 1 September 2006
Determination of the functional relationship between the transforming growth factor-β (TGFβ) receptor proteins endoglin and ALK1 is essential to the understanding of the human vascular disease,… Expand
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- S. Kummar, A. Oza, +20 authors J. Doroshow
- Medicine
- Clinical Cancer Research
- 14 January 2015
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative… Expand
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.
- Kevin Dobbin, D. Beer, +18 authors T. Giordano
- Biology, Medicine
- Clinical cancer research : an official journal of…
- 15 January 2005
A key step in bringing gene expression data into clinical practice is the conduct of large studies to confirm preliminary models. The performance of such confirmatory studies and the transition to… Expand
Novel biochemical pathways of endoglin in vascular cell physiology
- C. Bernabeu, B. Conley, C. Vary
- Biology, Medicine
- Journal of cellular biochemistry
- 15 December 2007
The broad role of the transforming growth factor beta (TGFβ) signaling pathway in vascular development, homeostasis, and repair is well appreciated. Endoglin is emerging as a novel, complex, and… Expand
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies
- S. Kummar, M. Gutiérrez, +15 authors A. Murgo
- Medicine
- Clinical Cancer Research
- 15 September 2007
Purpose: MS-275 is a histone deacetylase inhibitor that has shown potent and unique anticancer activity in preclinical models. The aims of this phase I trial were to determine the dose-limiting… Expand